CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 624-638

  Schürch, Christian ^a   Riether, Carsten ^a   Matter, Matthias S ^b   Tzankov, Alexandar ^b   Ochsenbein, Adrian F ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; CD27 ANTIGEN; CD70 ANTIGEN; NCK INTERACTING KINASE; PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; WNT PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE MARROW; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; DENDRITIC CELL; GENE TARGETING; IMMUNE SYSTEM; LEUKEMIA STEM CELL; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL;

ADAPTIVE IMMUNITY; ADULT; AGED; ANIMALS; ANTIGENS, CD27; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; STEM CELL TRANSPLANTATION; TNF RECEPTOR-ASSOCIATED FACTOR 2; WNT PROTEINS; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84856512553     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45977     Document Type: Article

References (56)

1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079-1082.
3. Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008;26(17):2911-2915.
4. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-172. (Pubitemid 29325745)
5. Molldrem JJ, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
6. Van Driessche A, et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia. 2005;19(11):1863-1871. (Pubitemid 41553993)
7. Pierson BA, Miller JS. The role of autologous natural killer cells in chronic myelogenous leukemia. Leuk Lymphoma. 1997;27(5-6):387-399. (Pubitemid 28029901)
8. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767-776. (Pubitemid 38129531)
9. Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood. 2009;113(19):4681-4689.
10. Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114(8):1528-1536.
11. Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol. 1998;10(6):423-434. (Pubitemid 28564371)
12. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev. 2009;229(1):216-231.
13. Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001;33(1):19-32. (Pubitemid 32146464)
14. van Oosterwijk MF, et al. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int Immunol. 2007;19(6):713-718. (Pubitemid 47078715)
15. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17(3):275-281. (Pubitemid 40692662)
16. Wiesmann A, et al. Expression of CD27 on murine hematopoietic stem and progenitor cells. Immunity. 2000;12(2):193-199. (Pubitemid 30398633)
17. Nolte MA, et al. Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol. 2005;6(4):412-418. (Pubitemid 41716782)
18. Tesselaar K, et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003;170(1):33-40. (Pubitemid 36026120)
19. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271-285.
20. Neering SJ, et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007;110(7):2578-2585. (Pubitemid 47523181)
21. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404(6774):193- 197. (Pubitemid 30154488)
22. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000;1(5):433-440.
23. Merchant A, Joseph G, Wang Q, Brennan S, Matsui W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood. 2010;115(12):2391-2396.
24. Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol. 2005;5(1):21-30. (Pubitemid 40070328)
25. Coluccia AM, et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007;26(5):1456-1466. (Pubitemid 46398694)
26. Fu CA, Shen M, Huang BC, Lasaga J, Payan DG, Luo Y. TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J Biol Chem. 1999;274(43):30729-30737.
27. Mahmoudi T, et al. The kinase TNIK is an essential activator of Wnt target genes. EMBO J. 2009;28(21):3329-3340.
28. Shitashige M, et al. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res. 2010;70(12):5024-5033.
29. Wang Y, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
30. Goessling W, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009;136(6):1136-1147.
31. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24-37. (Pubitemid 43053650)
32. Lim SH, Coleman S. Chronic myeloid leukemia as an immunological target. Am J Hematol. 1997;54(1):61-67. (Pubitemid 27013904)
33. Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol. 2008;80(6):461-468. (Pubitemid 351677457)
34. Jaiswal S, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271-285.
35. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med. 2007;13(11):470-481. (Pubitemid 350086980)
36. Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-299.
37. Huntly BJ, Gilliland DG. Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer Cell. 2004;6(3):199-201. (Pubitemid 39222031)
38. Huntly BJ, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6(6):587-596. (Pubitemid 40017702)
39. Jamieson CH, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667. (Pubitemid 39063268)
40. Jamieson CH, Weissman IL, Passegue E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell. 2004;6(6):531-533. (Pubitemid 40017695)
41. Rizo A, Vellenga E, de Haan G, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet. 2006;15 spec no 2:R210-R219. (Pubitemid 44446796)
42. Sandy AR, Maillard I. Notch signaling in the hematopoietic system. Expert Opin Biol Ther. 2009;9(11):1383-1398.
43. Maillard I, et al. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2(4):356-366. (Pubitemid 351455243)
44. Friedman AD. Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol. 2009;219(3):520-524.
45. Roche-Lestienne C, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008;111(7):3735-3741.
46. Penther D, et al. Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. Leukemia. 2002;16(6):1131-1134. (Pubitemid 34618850)
47. Mikhail FM, et al. A new translocation that rearranges the AML1 gene in a patient with T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2002;135(1):96-100. (Pubitemid 34601179)
48. Miething C, et al. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci U S A. 2007;104(11):4594-4599. (Pubitemid 47186270)
49. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3(8):609-620. (Pubitemid 37328664)
50. Hughes TP, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432. (Pubitemid 37211057)
51. Zhao C, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12(6):528-541. (Pubitemid 350199070)
52. Lansdorp PM, Smith C, Thornbury G, Little MT, Dragowska W. Reactivity of workshop mAb with CD34+ bone marrow cells. In: Schlossman SF, et al., eds. Leucocyte Typing V: White Cell Differentiation Antigens. New York, New York, USA: Oxford University Press; 1995:1030-1032.
53. Eaves CJ, Humphries RK. Acute myeloid leukemia and the Wnt pathway. N Engl J Med. 2010;362(24):2326-2327.
54. Arens R, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity. 2001;15(5):801-812. (Pubitemid 34008507)
55. Martin SJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182(5):1545-1556.
56. Reya T, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423(6938):409-414. (Pubitemid 36626987)